Introduction
Bexitrol F Inhalation Capsule 50 mcg+100 mcg is a combination medication used to manage and prevent asthma and chronic obstructive pulmonary disease (COPD) symptoms. Salmeterol is a long-acting beta-agonist (LABA), and Fluticasone Propionate is a corticosteroid. Together, they help to control airway inflammation and bronchoconstriction.
Uses
This combination medication is used for:
- Long-term management of asthma in patients aged 4 years and older.
- Management of chronic obstructive pulmonary disease (COPD) to reduce symptoms and prevent exacerbations.
- Improving lung function and reducing the frequency of asthma attacks or COPD flare-ups.
| Brand Name | Bexitrol F |
|---|---|
| Type | Inhalation Capsule |
| Weight | 50 mcg+100 mcg |
| Generic | Salmeterol + Fluticasone Propionate |
| Manufacturer | Beximco Pharmaceuticals Ltd. |
| Available in | English বাংলা |
Mechanism of Action
Salmeterol works by stimulating beta-2 adrenergic receptors in the airways, leading to relaxation of bronchial smooth muscle and bronchodilation. This helps to open the airways and improve airflow. Fluticasone Propionate works by reducing inflammation in the airways through its corticosteroid action, decreasing mucus production and swelling. The combined effect of these medications helps to control symptoms and prevent respiratory issues.
How Long Does It Take to Work?
Salmeterol begins to work within 30 to 60 minutes of inhalation, with peak effects occurring in 3 to 4 hours. Its effects can last up to 12 hours. Fluticasone Propionate may take several days to weeks of consistent use to reach its full anti-inflammatory effect and show noticeable improvements in asthma or COPD symptoms.
Absorption
When inhaled, Salmeterol and Fluticasone Propionate are absorbed directly into the lungs, where they exert their effects. A small portion of Fluticasone Propionate is absorbed systemically through the respiratory tract, but its systemic absorption is minimal compared to its local effects in the lungs. Salmeterol also has minimal systemic absorption when used at recommended doses.
Route of Elimination
Fluticasone Propionate is metabolized primarily in the liver through cytochrome P450 enzymes, with its metabolites excreted in the feces. Salmeterol is also metabolized in the liver, with its metabolites excreted in the urine. Both drugs have a minimal systemic impact due to their localized action in the lungs.
Dosage
Inhaler:- Adults and adolescents 12 years and older: 2 puffs of 25 µg Salmeterol and 50 µg Fluticasone Propionate twice daily or 2 puffs of 25 µg Salmeterol and 125 µg Fluticasone Propionate twice daily or 2 puffs of 25 µg Salmeterol and 250 µg Fluticasone Propionate twice daily.
- Children (4-12 years): 2 puffs of 25 µg salmeterol and 50 µg Fluticasone Propionate twice daily.
Inhalation capsule (for asthma):
- Adult and Adolescent (12 Years and Older): Salmeterol 50 µg & Fluticasone 100 µg or Salmeterol 50 µg & Fluticasone 250 µg twice daily (morning and evening, approximately 12 hours apart).
- The recommended starting dosages for Salmeterol 50 µg & Fluticasone 100 µg & Salmeterol 50 µg & Fluticasone 250 µg for patients aged 12 years and older are based upon patients asthma severity.
- The maximum recommended dosage is Salmeterol 50 µg & Fluticasone 500 µg twice daily.
- Pediatric Patients (4 to 11 Years): For patients with asthma who are not controlled on an inhaled corticosteroid, the dosage is Salmeterol 50 µg & Fluticasone 100 µg twice daily (morning and evening, approximately 12 hours apart).
Maxhaler (For Asthma): This is a moulded plastic device containing a foil strip with 60 regularly placed blisters containing pre-dispensed inhalation powder. Patients should be made aware that inhaler must be used daily for optimum benefit, even when asymptomatic.
Adults and Adolescents (12 years and older)-
- 50/100 inhaler: One Inhalation twice daily
- 50/250 inhaler: One Inhalation twice daily
- 50/500 inhaler: One Inhalation twice daily
- 50/100 inhaler: One Inhalation twice daily. The maximum licensed dose of fluticasone propionate delivered by this inhaler in children is 100 mcg twice daily. There are no data available for use of this inhaler in children aged under 4 years.
- Inhaler: One Inhalation twice daily
- Special patient groups: There is no need to adjust the dose in elderly patients or in those with renal impairment. There are no data available for use of this in patients with hepatic impairment.
- Using the inhaler: This is a patient friendly, ready to use and easy to grip device. Use as per instructions for use.
The dosage of Bexitrol F Inhalation Capsule 50 mcg+100 mcg varies depending on the specific product and the patient's condition. Commonly used dosages include:
- One inhalation of the combination product twice daily (morning and evening), with dosages typically ranging from 50/100 mcg to 50/250 mcg of Salmeterol/Fluticasone Propionate, respectively.
Dosage should be adjusted based on the patient's response and the severity of their condition.
Administration
The medication is administered via an inhaler. It is essential to use the inhaler properly to ensure effective delivery of the medication to the lungs. Patients should be instructed on the correct technique for inhalation and advised to rinse their mouth after use to prevent oral candidiasis.
Side Effects
Common side effects may include:
- Hoarseness or sore throat.
- Coughing or oral thrush.
- Headache.
- Muscle cramps or tremors.
Serious side effects can include:
- Adrenal suppression with long-term use of corticosteroids.
- Increased risk of pneumonia in COPD patients.
- Severe allergic reactions.
Toxicity
Signs of toxicity may include:
- Severe cardiovascular effects such as tachycardia or hypertension due to excessive Salmeterol.
- Systemic corticosteroid effects such as Cushing's syndrome from prolonged high doses of Fluticasone Propionate.
Management includes discontinuing the medication and providing symptomatic treatment as needed.
Precautions
Precautions include:
- Monitoring for potential signs of worsening asthma or COPD symptoms.
- Periodic assessment of adrenal function in patients on long-term therapy.
- Using with caution in patients with cardiovascular disease or diabetes due to potential effects of Salmeterol.
Interaction
Interactions may include:
- Potential interactions with other medications that affect liver enzymes (e.g., CYP3A4 inhibitors) which may increase systemic levels of Fluticasone Propionate.
- Use of other beta-agonists or sympathomimetic drugs, which may potentiate the effects of Salmeterol.
Disease Interaction
Use with caution in patients with:
- Cardiovascular diseases, as Salmeterol may exacerbate certain conditions.
- Diabetes, due to potential impact on blood glucose levels.
- Glaucoma or cataracts, due to corticosteroid effects.
Drug Interaction
Drug interactions include:
- Drug interactions with CYP3A4 inhibitors, which may increase Fluticasone Propionate levels.
- Interactions with other inhaled corticosteroids or LABAs which could increase the risk of side effects.
Food Interactions
There are no significant food interactions reported with Bexitrol F Inhalation Capsule 50 mcg+100 mcg. However, patients should maintain a healthy diet and avoid excessive caffeine, which could potentially exacerbate side effects of Salmeterol.
Pregnancy Use
Bexitrol F Inhalation Capsule 50 mcg+100 mcg is categorized as a Category C medication by the FDA. This means that risk cannot be ruled out. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult with a healthcare provider before use during pregnancy.
Lactation Use
Both Salmeterol and Fluticasone Propionate are excreted in breast milk in small amounts. The medication is generally considered safe for use during lactation, but it is advisable to consult a healthcare provider to discuss potential risks and to ensure that the benefits outweigh any potential risks to the infant.
Acute Overdose
In case of acute overdose, symptoms may include severe tachycardia, arrhythmias, or hypokalemia due to excessive Salmeterol. Corticosteroid overdose can lead to symptoms like Cushing’s syndrome. Treatment involves supportive care and management of symptoms. Medical attention should be sought immediately in the event of overdose.
Contraindication
Contraindications include:
- Known hypersensitivity to Salmeterol, Fluticasone Propionate, or any components of the formulation.
- Acute bronchospasm or severe asthma exacerbations where rapid-acting bronchodilators are needed.
Use Direction
Follow the prescribed dosage and administration instructions. Use the inhaler consistently at the recommended times and avoid abrupt discontinuation. Rinse the mouth after each use to prevent oral thrush and adhere to any additional guidelines provided by the healthcare provider.
Storage Conditions
Store the inhaler at room temperature, away from direct heat and moisture. Keep it in its original packaging and ensure it is securely closed when not in use. Avoid freezing or exposing the inhaler to extreme temperatures.
Volume of Distribution
The volume of distribution for Fluticasone Propionate is approximately 0.6 L/kg, indicating extensive distribution to tissues. Salmeterol has a moderate volume of distribution due to its lipophilic nature, which allows it to bind to lung tissue effectively.
Half Life
The half-life of Fluticasone Propionate is approximately 8 hours, while Salmeterol has a half-life of about 5 to 9 hours. The duration of action is prolonged due to the nature of the inhaled medication, providing sustained relief of symptoms.
Clearance
Fluticasone Propionate is cleared primarily through hepatic metabolism, with its metabolites excreted in the feces. Salmeterol is also metabolized by the liver and excreted primarily in the urine. Clearance rates may be influenced by liver function and other patient-specific factors.
See in details version Bexitrol F Inhalation Capsule 50 mcg+100 mcg also Bexitrol F Inhalation Capsule 50 mcg+100 mcg in bangla
Social card
Some Frequently Asked Questions About Bexitrol F Inhalation Capsule 50 mcg+100 mcg
